ArticleOncotarget2012

Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?

Anouk Caraux et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.